Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate; hyprolose; maize starch; iron oxide red - treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

remedyrepack inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - aripiprazole tablets are indicated for the treatment of: - schizophrenia [ see clinical studies ( 14.1) ] additional pediatric use information is approved for otsuka america pharmaceutical, inc.’s abilify ® (aripiprazole) product. however, due to otsuka america pharmaceutical, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [ see adverse reactions ( 6.2) ]. pregnancy category c pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to aripiprazole during pregnancy. for more information contact the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. risk summary neonates exposed to antipsychotic drugs (including aripiprazole) d

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

remedyrepack inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 30 mg - aripiprazole oral tablets are indicated for the treatment of: • schizophrenia [see clinical studies ( 14.1 )] additional pediatric use information is approved for otsuka america pharmaceutical, inc.'s abilify ® (aripiprazole) product. however, due to otsuka america pharmaceutical, inc.'s marketing exclusivity rights, this drug product is not labeled with that information. aripiprazole tablets are contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . teratogenic effects pregnancy category c: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to aripiprazole during pregnancy. for more information contact the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. risk summary

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

proficient rx lp - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - aripiprazole oral tablets are indicated for the treatment of: additional pediatric use information is approved for otsuka america pharmaceutical, inc.’s abilify® (aripiprazole) product. however, due to otsuka america pharmaceutical, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. aripiprazole tablets are contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] .  pregnancy category c pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to aripiprazole during pregnancy. for more information contact the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. risk summary neonates exposed to antipsychotic drugs (including aripiprazole) during the third trimester of pregnancy

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

sciegen pharmaceuticals inc - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 10 mg - aripiprazole orally disintegrating tablets are indicated for the treatment of: - schizophrenia [ see clinical studies ( 14.1) ] - irritability associated with autistic disorder [see clinical studies ( 14.4)] - treatment of tourette’s disorder [see clinical studies ( 14.5)] additional pediatric use information is approved for otsuka america pharmaceutical, inc.’s abilify ® (aripiprazole) product. however, due to otsuka america pharmaceutical, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [ see adverse reactions ( 6.2) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including aripiprazole, during pregnancy. healthcare providers

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; iron oxide red; tartaric acid; croscarmellose sodium; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 20 mg - tablet, uncoated - excipient ingredients: tartaric acid; croscarmellose sodium; microcrystalline cellulose; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; iron oxide yellow; croscarmellose sodium; tartaric acid; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; tartaric acid; indigo carmine aluminium lake; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

solco healthcare u.s., llc - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - aripiprazole tablets are indicated for the treatment of: aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including aripiprazole, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. risk summary neonates exposed to antipsychotic drugs, including aripiprazole, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery (see clinical considerations) . overall available data from published epidemiologic studies of pregnant women exposed to aripiprazole have not est